Peptide-Engineered Seliciclib Nanomedicine for Brain-Targeted Delivery and Neuroprotection

Area of Science:

• Neuroscience
• Nanotechnology
• Pharmacology

Background:

• Seliciclib, a cyclin-dependent kinase 5 (CDK5) inhibitor, shows neuroprotective promise.
• Poor blood-brain barrier (BBB) permeability limits seliciclib's therapeutic use.
• Nanoparticle (NP) drug delivery systems offer potential solutions for BBB penetration.

Purpose of the Study:

• To develop BBB-targeting polymeric nanoparticles (NPs) for enhanced seliciclib delivery.
• To evaluate the in vitro and in vivo performance of peptide-modified NPs.
• To assess the neuroprotective efficacy of seliciclib-loaded NPs.

Main Methods:

• Polymeric NPs encapsulating seliciclib were synthesized.
• NPs were modified with a BBB-targeting peptide ligand (His-Ala-Ile-Tyr-Pro-Arg-His).
• In vitro cell monolayer transport and in vivo biodistribution studies were conducted.
• Neuroprotection was evaluated against 1-methyl-4-phenylpyridinium (MPP⁺) in SH-SY5Y cells.

Main Results:

• Peptide-modified NPs showed significantly higher translocation across a bEnd.3 cell monolayer compared to unmodified NPs.
• In vivo studies revealed a 3.38-fold increase in brain accumulation for peptide-modified NPs.
• Seliciclib-loaded, peptide-conjugated NPs demonstrated significant neuroprotection against MPP⁺.

Conclusions:

• BBB-targeting peptide modification enhances NP brain delivery.
• This nanodelivery system effectively overcomes BBB limitations for seliciclib.
• Peptide-conjugated, seliciclib-loaded NPs represent a promising strategy for neuroprotection.